Bromantane 100x30mg

NOT FOR HUMAN CONSUMPTION

Bromantane is an adamantane-derived actoprotector developed in Russia and marketed there as Ladasten® for asthenic syndrome. Pharmacologically it behaves as a pro-dopaminergic, anxiolytic psychostimulant with adaptogenic and immunomodulatory signals. Unlike classic stimulants, it up-regulates catecholamine synthesis(rather than driving acute release), with reported increases in tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC) expression, plus mild GABAergic and serotonergic modulation. It is not approved in the US/EU and is prohibited in sport (stimulants class).

Additional Benefits of Bromantane Now Under Investigation

2. Molecular Mechanism of Action

2.1 Receptor/enzymatic pharmacodynamics

• Dopaminergic: Up-regulates TH (rate-limiting for DA) and AADC, increasing de novo dopamine synthesis and mesolimbic/striatal DA tone without vesicular dump; may elevate BDNF transcripts in cortex/hippocampus.

• GABA/5-HT modulation: Mild GABA-ergic normalization and 5-HT turnover changes reported (contributing to anxiolysis).

• Mitochondrial/actoprotector: ↑ activity of succinate dehydrogenase, cytochrome oxidase, and antioxidant systems under load.

2.2 Down-stream biology

3. Pharmacokinetics

• Route: Oral tablets/capsules.

• Onset: Days for anxiolytic/activation profile; anti-fatigue often within 1–2 weeks.

• Half-life: Reported in the hours-to low teens (compound and metabolite-dependent); once-daily dosing typical in Russian practice.

• Metabolism: Hepatic (oxidation/hydroxylation of adamantane/phenyl moieties) with renal/biliary excretion; minimal CYP interaction data published.

4. Clinical Evidence (high-level)

• Asthenic/neurasthenic syndromes: Randomized and open-label Russian trials show clinician-rated and patient-reported improvements vs baseline and some actives/placebo on asthenia and anxiety scales, with good tolerability.

• Operational stress studies: Controlled field studies (military/industrial) report better vigilance and psychomotor output in heat/sleep restriction vs comparators.

• Cognition: Mixed results, benefit most evident under fatigue or stress load; limited effect in well-rested healthyvolunteers.

Evidence quality note: Many trials are regional, with varying blinding/reporting standards; replication in multicenter, modern RCTs is limited. Extrapolation to unrelated conditions should be conservative.

5. Emerging Clinical Interests

6. Safety and Tolerability

• Common (usually mild): Dry mouth, insomnia (early weeks), headache, nausea, restlessness, sweating; often resolve with dose-timing (morning) or brief dose reduction.

• Less common: Tachycardia, BP drift, tremor, irritability; rare rash or dyspepsia.

• Neuropsychiatric: Generally anxiolytic, but activation can unmask anxiety in some, monitor if panic-prone. Mania/psychosis is rare; caution with bipolar history.

• Dependence/withdrawal: Low relative to amphetamines; no classic rebound when tapered.

• Hepatic/renal: Routine labs typically stable; avoid with significant hepatic disease until more data.

• Drug interactions: Limited data; be cautious with MAOIs, strong dopaminergics, and CNS stimulants (additive activation).

• Pregnancy/lactation: Insufficient data, avoid.

• Sport/anti-doping: Banned by WADA (stimulants). Detection persists days after dosing.

Comparative matrix

7. Regulatory Landscape

• Approved use: Russia/CIS (asthenic syndrome).

• US/EU: Not approved; available only as research chemical/import (quality variable).

• Sport: Prohibited substance (stimulants). High-profile positives drove early bans.

8. Practical Use & Dosing (where legal)

• Typical ranges: 50–100 mg once daily (morning) for 2–4 weeks, extend to 8–12 weeks if needed; some protocols use 100–200 mg/day in divided doses under supervision.

• Titration tips: Start 50 mg qAM, advance after 3–7 days if insomnia or jitteriness absent. Pair with sleep hygiene, hydration, electrolytes, and protein during heavy training/work.

• When to avoid/stop: Persistent insomnia, tachyarrhythmia, marked anxiety, or BP >140/90 despite timing/dose changes.

Selected References

• Neuroscience & Behavioral Physiology; Human Physiology, Actoprotector concept, performance under heat/sleep restriction; mitochondrial and antioxidant markers.

• Zhurnal Nevrologii i Psikhiatrii; CNS Drugs, Clinical studies in asthenia/neurasthenia: anxiolysis with activation, clinician-rated outcomes.

• Biochemistry (Moscow); Bulletin of Experimental Biology and Medicine, Up-regulation of TH/AADC, dopaminergic signaling, and mitochondrial enzymes.

• International Immunopharmacology, Interferon/IgA/NK changes (stress-linked immunomodulation).

• Autonomic Neuroscience; Psychophysiology, Autonomic balance and vigilance metrics under load.

• Drug Testing & Analysis; WADA Code, Anti-doping status, detection windows, historical cases.